Alimta Beats Gemcitabine In Some NSCLC Types
This article was originally published in The Pink Sheet Daily
But Phase III results show similar efficacy in patients overall.
You may also be interested in...
Maintenance therapy with Lilly’s pemetrexed shows increase in progression-free survival in the only drug-related abstract in ASCO’s press call.
Goal is to launch an average of two products per year by 2011 and three a year starting in 2014, CEO Taurel says.
Clinical trials show Alimta plus cisplatin has a three-month survival advantage over cisplatin alone. Lilly has submitted a supplemental application for treatment of second-line non-small cell lung cancer.